JANX logo

JANX
Janux Therapeutics Inc

1,624
Mkt Cap
$936.2M
Volume
572,420.00
52W High
$35.34
52W Low
$12.12
PE Ratio
-8.39
JANX Fundamentals
Price
$15.19
Prev Close
$15.39
Open
$15.38
50D MA
$14.07
Beta
1.41
Avg. Volume
1.16M
EPS (Annual)
-$1.83
P/B
0.97
Rev/Employee
$91,743.12
$89.28
Loading...
Loading...
News
all
press releases
Will Acute Care Strength Help Universal Health Offset Q1 Rising Costs?
UHS heads into Q1 earnings with acute care and behavioral health growth, but rising labor and supply costs could cloud the outlook.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Will Higher Costs & Lower Occupancy Impact HCA's Q1 Earnings?
HCA Healthcare heads into Q1 earnings with higher costs, lower occupancy and shorter stays weighing on results despite revenue growth.
Zacks·2d ago
News Placeholder
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the fourteen ratings firms that are presently covering the company...
MarketBeat·7d ago
News Placeholder
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first patient has been dosed...
Business Wire·7d ago
News Placeholder
Will Health Benefits Weakness Drag Elevance's Q1 Earnings?
ELV heads into its April 22 Q1 report with EPS likely down 11.4% as Health Benefits operating income is projected to plunge 13.7% year over year.
Zacks·7d ago
News Placeholder
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down - What's Next?
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down - Time to Sell...
MarketBeat·8d ago
News Placeholder
Short Interest in Janux Therapeutics, Inc. (NASDAQ:JANX) Decreases By 22.7%
Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totaling 7,744,629 shares, a...
MarketBeat·9d ago
News Placeholder
Janux Therapeutics (NASDAQ:JANX) Raised to "Hold" at Wall Street Zen
Wall Street Zen raised shares of Janux Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday...
MarketBeat·19d ago
News Placeholder
Janux Therapeutics Secures $35M Milestone Payment From BMY Deal
JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, signaling progress in its tumor-activated therapy platform.
Zacks·21d ago
News Placeholder
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development...
Business Wire·22d ago
<
1
2
...
>

Latest JANX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.